Buchholz UJ, et al. - Researchers administered an intranasal dose of 10^5.3 plaque-forming units (PFU) of RSV cold-passage/stabilized 2 (RSVcps2) vaccine candidate or placebo to RSV-seronegative 6–24-month-old children and assessed RSV serum neutralizing antibody titers before and 56 days after vaccination, vaccine virus infectivity, reactogenicity, and genetic stability. Findings suggested that in 6–24-month-old RSV-seronegative children, RSVcps2 was well tolerated and moderately immunogenic and had increased genetic stability.